Leydig cell aging and hypogonadism

Experimental Gerontology

Volumn 68, Issue , 2015, Pages 87-91

  Beattie, M C ^a   Adekola, L ^a   Papadopoulos, V ^b,c   Chen, H ^a   Zirkin, B R ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Aging; Hypogonadism; Testosterone; TSPO

Indexed keywords

CELL PROTEIN; CHOLESTEROL; CHOLESTEROL MONOOXYGENASE (SIDE CHAIN CLEAVING); CYCLIC AMP; GLUTATHIONE; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; LUTEINIZING HORMONE; N,N DIHEXYL 2 (4 FLUOROPHENYL)INDOLE 3 ACETAMIDE; PREGNENOLONE; REACTIVE OXYGEN METABOLITE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROIDOGENIC ACUTE REGULATORY PROTEIN; TESTOSTERONE; TRANSLOCATOR PROTEIN; UNCLASSIFIED DRUG; 4 AMINOBUTYRIC ACID RECEPTOR; PHOSPHOPROTEIN; TSPO PROTEIN, HUMAN;

CANCER RISK; CARDIOVASCULAR RISK; CELL AGING; CELL FUNCTION; CELL MEMBRANE FLUIDITY; CELL STIMULATION; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DNA DAMAGE; DRUG EFFECT; DRUG MECHANISM; ENZYME MODIFICATION; GENE EXPRESSION; HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LEYDIG CELL; LIPID PEROXIDATION; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; RISK BENEFIT ANALYSIS; SPERMATOGENESIS; STEROIDOGENESIS; STRESS; TESTOSTERONE BLOOD LEVEL; ANIMAL; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; RAT;

ANIMALS; CELL AGING; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; LEYDIG CELLS; MALE; PHOSPHOPROTEINS; RATS; RECEPTORS, GABA; TESTOSTERONE;

EID: 84937617513     PISSN: 05315565     EISSN: 18736815     Source Type: Journal    
DOI: 10.1016/j.exger.2015.02.014     Document Type: Review

References (74)

1. Abadilla K.A., Dobs A.S. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs 2012, 72:1591-1603.
2. Anderson M.E. Glutathione: an overview of biosynthesis and modulation. Chem. Biol. Interact. 1998, 111-112:1-14.
3. Araujo A.B., Esche G.R., Kupelian V., O'Donnell A.B., Travison T.G., Williams R.E., Clark R.V., McKinlay J.B. Prevalence of symptomatic androgen deficiency in men. J. Clin. Endocrinol. Metab. 2007, 92:4241-4247.
4. Azhar S., Cao L., Reaven E. Alteration of the adrenal antioxidant defense system during aging in rats. J. Clin. Invest. 1995, 96:1414-1424.
5. Beattie M.C., Chen H., Fan J., Papadopoulos V., Miller P., Zirkin B.R. Aging and luteinizing hormone effects on reactive oxygen species production and DNA damage in rat Leydig cells. Biol. Reprod. 2013, 88:1-7.
6. Belchetz P.E., Barth J.H., Kaufman J.M. Biochemical endocrinology of the hypogonadal male. Ann. Clin. Biochem. 2010, 47:503-515.
7. Bhasin S., Basaria S. Diagnosis and treatment of hypogonadism in men. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25:251-270.
8. Bobjer J., Naumovska M., Giwercman Y.L., Giwercman A. High prevalence of androgen deficiency and abnormal lipid profile in infertile men with non-obstructive azoospermia. Int. J. Androl. 2012, 35:688-694.
9. Bonavera J.J., Swerdloff R.S., Leung A., Lue Y.H., Baravarian S., Superiano L., Sinha-Hikim A.P., Wang C. In the male Brown-Norway (BN) male rat, reproductive aging is associated with decreased LH-pulse amplitude and area. J. Androl. 1997, 18:359-365.
10. Bonavera J.J., Swerdloff R.S., Sinha-Hakim A.P., Lue Y.H., Wang C. Aging results in attenuated gonadotropin releasing hormone-luteinizing hormone axis responsiveness to glutamate receptor agonist N-methyl-d-aspartate. J. Neuroendocrinol. 1998, 10:93-99.
11. Bosland M.C. Testosterone treatment is a potent tumor promoter for the rat prostate. Endocrinology 2014, 155:1-5.
12. Cao L., Leers-Sucheta S., Azhar S. Aging alters the functional expression of enzymatic and non-enzymatic anti-oxidant defense systems in testicular rat Leydig cells. J. Steroid Biochem. Mol. Biol. 2004, 88:61-67.
13. Chen H., Zirkin B.R. 1999 Long-term suppression of Leydig cell steroidogenesis prevents Leydig cell aging. Proc. Natl. Acad. Sci. 1999, 96:14877-14881.
14. Chen H., Hardy M.P., Huhtaniemi I., Zirkin B.R. Age-related decreased Leydig cell testosterone production in the brown Norway rat. J. Androl. 1994, 15:551-557.
15. Chen H., Huhtaniemi I., Zirkin B.R. Depletion and repopulation of Leydig cells in the testes of aging brown Norway rats. Endocrinology 1996, 137:3447-3452.
16. Chen H., Cangello D., Benson S., Folmer J., Zhu H., Trush M.A., Zirkin B.R. Age-related increase in mitochondrial superoxide generation in the testosterone-producing cells of brown Norway rat testes: relationship to reduced steroidogenic function?. Exp. Gerontol. 2001, 36:1361-1373.
17. Chen H., Hardy M.P., Zirkin B.R. Age-related decreases in Leydig cell testosterone production are not restored by exposure to LH in vitro. Endocrinology 2002, 143:1637-1642.
18. Chen H., Liu J., Luo L., Zirkin B.R. Dibutyryl cyclic adenosine monophosphate restores the ability of aged Leydig cells to produce testosterone at the high levels characteristic of young cells. Endocrinology 2004, 145:4441-4446.
19. Chen H., Pechenino A.A., Liu J., Beattie M.C., Brown T.R., Zirkin B.R. Effect of glutathione depletion on Leydig cell steroidogenesis in young and old brown Norway rats. Endocrinology 2008, 149:2612-2619.
20. Chung J.Y., Chen H., Midzak A., Burnett A.L., Papadopoulos V., Zirkin B.R. Drug ligand-induced activation of translocator protein (TSPO) stimulates steroid production by aged brown Norway rat Leydig cells. Endocrinology 2013, 154:2156-2165.
21. Culty M., Luo L., Yao Z.X., Chen H., Papadopoulos V., Zirkin B.R. Cholesterol transport, peripheral benzodiazepine receptor, and steroidogenesis in aging Leydig cells. J. Androl. 2002, 23:439-447.
22. Diemer T., Allen J.A., Hales K.H., Hales D.B. Reactive oxygen disrupts mitochondria in MA-10 tumor Leydig cells and inhibits steroidogenic acute regulatory (StAR) protein and steroidogenesis. Endocrinology 2003, 144:2882-2891.
23. Dobs A.S., Meikle A.W., Arver S., Sanders S.W., Caramelli K.E., Mazer N.A. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J. Clin. Endocrinol. Metab. 1999, 84:3469-3478.
24. Drew B., Leeuwenburgh C. Aging and the role of reactive nitrogen species. Ann. N. Y. Acad. Sci. 2002, 959:66-81.
25. Fang Y.Z., Yang S., Wu G. Free radicals, antioxidants, and nutrition. Nutrition 2002, 18:872-879.
26. Finkel T., Holbrook N.J. Oxidants, oxidative stress and the biology of ageing. Nature 2000, 408:239-247.
27. Finkle W.D., Greenland S., Ridgeway G.K., Adams J.L., Frasco M.A., Cook M.B., Fraumeni J.F., Hoover R.N. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One 2014, 9:e85805.
28. Georgiou M., Perkins L.M., Payne A.H. Steroid synthesis-dependent, oxygen-mediated damage of mitochondrial and microsomal cytochrome P-450 enzymes in rat Leydig cell cultures. Endocrinology 1987, 121:1390-1399.
29. Gooren L.J., Bunck M.C.M. Transdermal testosterone delivery: testosterone patch and gel. World J. Urol. 2003, 21:316-319.
30. Griffith O.W. Biologic and pharmacologic regulation of mammalian glutathione synthesis. Free Radic. Biol. Med. 1999, 27:922-935.
31. Griffith O.W., Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J. Biol. Chem. 1979, 254:7558-7560.
32. Gruenewald D.A., Matsumoto A.M. Testosterone supplementation therapy for older men: potential benefits and risks. J. Am. Geriatr. Soc. 2003, 51:101-115.
33. Hamada A.J., Montgomery B., Agarwal A. Male infertility: a critical review of pharmacologic management. Expert. Opin. Pharmacother. 2012, 13:2511-2531.
34. Harman S.M., Metter J., Tobin J.D., et al. Longitudinal effects of aging on serum total free testosterone levels in healthy men. Baltimore longitudinal study of aging. J. Clin. Endocrinol. Metab. 2001, 86:724-731.
35. Hornsby P.J. Steroid and xenobiotic effects on the adrenal cortex: mediation by oxidative and other mechanisms. Free Radic. Biol. Med. 1989, 6:103-115.
36. Hwang K., Walters R.C., Lipshultz L.I. Contemporary concepts in the evaluation and management of male infertility. Nat. Rev. Urol. 2011, 8:86-94.
37. Jones D.P., Mody V.C., Carlson J.L., Lynn M.J., Sternberg P. Redox analysis of human plasma allows separation of pro-oxidant events of aging from decline in antioxidant defenses. Free Radic. Biol. Med. 2002, 33:1290-1300.
38. Kim H.H., Schlegel P.N. Endocrine manipulation in male infertility. Urol. Clin. N. Am. 2008, 35:303-318.
39. Kodaman P.H., Aten R.F., Behrman H.R. Lipid hydroperoxides evoke antigonadotropic and antisteroidogenic activity in rat luteal cells. Endocrinology 1994, 135:2723-2730.
40. Kolena J., Blazícek P., Horkovics-Kováts S., Ondrias K., Seböková E. Modulation of rat testicular LH/hCG receptors by membrane lipid fluidity. Mol. Cell. Endocrinol. 1986, 44:69-76.
41. Li W.R., Chen L., Chang Z.J., Xin H., Liu T., Zhang Y.Q., Li G.Y., Zhou F., Gong Y.Q., Gao Z.Z., Xin Z.C. Autophagic deficiency is related to steroidogenic decline in aged rat Leydig cells. Asian J. Androl. 2011, 13:881-888.
42. Liao C., Reaven E., Azhar S. Age-related decline in the steroidogenic capacity of isolated rat Leydig cells: a defect in cholesterol mobilization and processing. J. Steroid Biochem. Mol. Biol. 1993, 46:39-47.
43. Liu R.M. Down-regulation of γ-glutamylcysteine synthetase regulatory subunit gene expression in rat brain tissue during aging. J. Neurosci. Res. 2002, 68:344-351.
44. Liu H., Wang H., Shenvi S., Hagen T.M., Liu R.M. Glutathione metabolism during aging and in Alzheimer disease. Ann. N. Y. Acad. Sci. 2004, 1019:346-349.
45. Luo L., Chen H., Zirkin B.R. Are Leydig cell steroidogenic enzymes differentially regulated with aging?. J. Androl. 1996, 17:509-515.
46. Luo L., Chen H., Zirkin B.R. Leydig cell aging: steroidogenic acute regulatory protein (StAR) and cholesterol side-chain cleavage enzyme. J. Androl. 2001, 22:149-156.
47. Luo L., Chen H., Zirkin B.R. Temporal relationships among testosterone production, steroidogenic acute regulatory protein (StAR), and P450 side-chain cleavage enzyme (P450scc) during Leydig cell aging. J. Androl. 2005, 26:25-31.
48. Luo L., Chen H., Trush M.A., Show M.D., Anway M.D., Zirkin B.R. Aging and the brown Norway rat Leydig cell antioxidant defense system. J. Androl. 2006, 27:240-247.
49. Matsumoto A.M. Andropause: clinical implications of the decline in serum testosterone levels with aging in men. J. Gerontol. A Biol. Sci. Med. Sci. 2002, 57:M76-M99.
50. Miller W.L., Bose H.S. Early steps in steroidogenesis: intracellular cholesterol trafficking. J. Lipid Res. 2011, 52:2111-2135.
51. Mohr B.A., Guay A.T., O'Donnell A.B., McKinlay J.B. Normal, bound and nonbound testosterone levels in normally ageing men: results from the Massachusetts male ageing study. Clin. Endocrinol. 2005, 62:64-73.
52. Nothdurfter C., Rammes G., Baghai T.C., Schüle C., Schumacher M., Papadopoulos V., Rupprecht R. Translocator protein (18kDa) as a target for novel anxiolytics with a favourable side-effect profile. Neuroendocrinology 2012, 24:82-92.
53. Page S.T. Physiologic role and regulation of intratesticular sex steroids. Curr. Opin. Endocrinol. Diabetes Obes. 2011, 18:217-223.
54. Pavlovich C.P., King P., Goldstein M., Schlegel P.N. Evidence of a treatable endocrinopathy in infertile men. J. Urol. 2001, 165:827-841.
55. Peltola V., Huhtaniemi I., Metsa-Ketela T., Ahotupa M. Induction of lipid peroxidation during steroidogenesis in the rat testis. Endocrinology 1996, 137:105-112.
56. Quinn P.G., Payne A.H. Oxygen-mediated damage of microsomal cytochrome P-450 enzymes in cultured Leydig cells. Role in steroidogenic desensitization. J. Biol. Chem. 1984, 259:4130-4135.
57. Quinn P.G., Payne A.H. Steroid product-induced, oxygen-mediated damage of microsomal cytochrome P-450 enzymes in Leydig cell cultures. Relationship to desensitization. J. Biol. Chem. 1985, 260:2092-2099.
58. Ramasamy R., Stahl P.J., Schlegel P.N. Medical therapy for spermatogenic failure. Asian J. Androl. 2011, 14:57-60.
59. Rone M.B., Fan J., Papadopoulos V. Cholesterol transport in steroid biosynthesis: role of protein-protein interactions and implications in disease states. Biochim. Biophys. Acta 2009, 1791:646-658.
60. Rupprecht R., Rammes G., Eser D., Baghai T.C., Schule C., Nothdurfter C., Troxler T., Gentsch C., Kalkman H.O., Chaperon F., Uzunov V., McAllister K.H., Bertaina-Anglade V., La Rochelle C.D., Tuerck D., Floesser A., Kiese B., Schumacher M., Landgraf R., Holsboer F., Kucher K. Translocator protein (18kD) as target for anxiolytics without benzodiazepine-like side effects. Science 2009, 325:490-493.
61. Sandhu S.K., Kaur G. Alterations in oxidative stress scavenger system in aging rat brain and lymphocytes. Biogerontology 2002, 3:161-173.
62. Schlegel P.N. Evaluation of male infertility. Minerva Ginecol. 2009, 61:261-283.
63. Sih R., Morley J.E., Kaiser F.E., Perry H.M., Patrick P., Ross C. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 1997, 82:1661-1667.
64. Sokanovic S.J., Baburski A.Z., Janjic M.M., Stojkov N.J., Bjelic M.M., Lalosevic D., Andric S.A., Stojilkovic S.S., Kostic T.S. The opposing roles of nitric oxide and cGMP in the age-associated decline in rat testicular steroidogenesis. Endocrinology 2013, 154:3914-3924.
65. Surampudi P.N., Wang C., Swerdloff R. Hypogonadism in the aging male diagnosis, potential benefits, and risks of testosterone replacement therapy. Int. J. Endocrinol. 2012, 2012:1-20.
66. Taliani S., Da Settimo F., Da Pozzo E., Chelli B., Martini C. Translocator protein ligands as promising therapeutic tools for anxiety disorders. Curr. Med. Chem. 2009, 16:3359-3380.
67. Vega M., Carrasco I., Castillo T., Troncoso J.L., Videla L.A., Devoto L. Functional luteolysis in response to hydrogen peroxide in human luteal cells. J. Endocrinol. 1995, 147:177-182.
68. Vigen R., O'Donnell C.I., Barón A.E., Grunwald G.K., Maddox T.M., Bradley S.M., Barqawi A., Woning G., Wierman M.E., Plomondon M.E., Rumsfeld J.S., Ho P.M. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013, 310:1829-1836.
69. Wang C., Leung A., Sinha-Hikim A.P. Reproductive aging in the male brown-Norway rat: a model for human. Endocrinology 1993, 133:2773-2781.
70. Wang C., Ilani N., Arvert S., McLachlan R.I., Soulis T., Watkinson A. Efficacy and safety of the 2% formulation of testosterone topical solution applied to the axillae in androgen-deficient men. Clin. Endocrinol. 2011, 75:836-843.
71. Wang F.F., Wang Q., Chen Y., Lin Q., Gao H.B., Zhang P. Chronic stress induces ageing-associated degeneration in rat Leydig cells. Asian J. Androl. 2012, 14:643-648.
72. Wu X., Yao K., Carlson J.C. Plasma membrane changes in the rat corpus luteum induced by oxygen radical generation. Endocrinology 1993, 133:491-495.
73. Wu F.C., Tajar A., Beynon J.M., Pye S.R., Silman A.J., Finn J.D., O'Neill T.W., Bartfai G., Casanueva F.F., Forti G., Giwercam A., Han T.S., Kula K., Lean M.E., Pendleton N., Punab M., Boonen S., Vanderschueren D., Labrie F., Huhtaniemi I.T. Identification of late-onset hypogonadism in middle-aged and elderly men. N. Engl. J. Med. 2010, 363:123-135.
74. Xu L., Freeman G., Cowling B.J., Schooling C.M. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013, 11:108.